Clinical trials: Moderate-to-severe Psoriasis
Psoriasis
An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.
- Trial name
- NCT03392337
- Testing
- Narrowband UVB phototherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Moderate to Severe Plaque Psoriasis
A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
This study estimates the treatment goal achievement rate, depicts the implementation of the Progressive Psoriasis Initiative (PPI) recommendations regarding treatment modifications and transitioning, and assesses patient…
- Trial name
- CONCORDIA (NCT02713295)
- Where
- 43 sites in Greece
- Volunteers
- 273 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.
- Trial name
- NCT02413229
- Testing
- DSXS1411
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Moderate to Severe Chronic Plaque-Type Psoriasis
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of…
- Trial name
- NCT01640951
- Testing
- AIN457 150 mg, AIN457 300 mg
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 675 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with moderate to severe plaque psoriasis will relieve signs and symptoms of the disease.
- Trial name
- NCT03168256
- Testing
- CF101 2mg, CF101 3mg, Apremilast 30mg
- Where
- 30 sites in Bosnia and Herzegovina, Bulgaria and 7 more
- Volunteers
- 528 people
- Sponsor
- Can-Fite BioPharma
Psoriasis
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
Add-on Enstilar to Otezla therapy.
- Trial name
- NCT03587194
- Testing
- Otezla
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Psoriasis
The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)
This is a Phase 3b, randomized, parallel-group, multicenter, active-controlled, open-label study of the efficacy and safety of infliximab compared with methotrexate (MTX) in the treatment of moderate to severe psoriasis in adults…
- Trial name
- NCT00251641
- Testing
- infliximab, methotrexate
- Volunteers
- 868 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis Vulgaris, Metabolic Syndrome
Analysis Of The Influence Of Metabolic Syndrome On Treatment Efficacy With Anti-Tnf In Moderate-Severe Psoriasis In Real Clinical Practice.
It has been reported in various epidemiological studies that patients with moderate-to-severe plaque psoriasis, with or without associated psoriatic arthritis, have an increased frequency of cardiovascular risk factors, such as…
- Trial name
- NCT01753245
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Juan Ruano
Psoriasis
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.
- Trial name
- NCT00329303
- Testing
- Certolizumab Pegol (Cimzia®)
- Where
- 14 sites in France, Germany
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Palmoplantar Pustulosis
Picankibart in Palmoplantar Pustulosis
1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to…
- Trial name
- NCT07552454
- Testing
- Picankibart
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Plaque Psoriasis
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis.
- Trial name
- AMAGINE-3 (NCT01708629)
- Testing
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab
- Where
- 157 sites in United States, Australia and 9 more
- Volunteers
- 1,881 people
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis, Psoriasis
Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy and safety of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection (Qiangke®) in the treatment of Moderate to Severe Plaque…
- Trial name
- NCT02701205
- Testing
- etanercept, etanercept (half dose)
- Where
- 4 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai Celgen Bio-Pharmaceutical Co.,Ltd
Psoriasis
Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis
The purpose of this research study is to better understand whether trichuris suis ova (TSO) ingested orally may be safe and effective in the treatment of psoriasis.
- Trial name
- NCT01948271
- Testing
- Trichuris Suis Ova
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Tufts Medical Center
Plaque Psoriasis
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045%…
- Trial name
- NCT05282771
- Testing
- Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
- Where
- United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Moderate-to-Severe Plaque Psoriasis
Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in Patients with Moderate-to-Severe Plaque Psoriasis
- Trial name
- NCT04839016
- Testing
- SHR-1314
- Volunteers
- 660 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chronic Plaque Psoriasis
Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The study is a prospective, multi-centre, observational study designed to assess the long-term effectiveness and safety of alefacept in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- AWARE-2 (NCT00795353)
- Testing
- Amevive exposure
- Where
- 21 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Astellas Pharma Inc
Psoriasis
BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis
The clinical objective of this study was to determine the effect of BIRB 796 BS on pharmacodynamic markers of psoriasis as a measure of efficacy, to determine the population pharmacokinetics of BIRB 796 BS and to determine the…
- Trial name
- NCT02209753
- Testing
- BIRB 796 BS, low dose, BIRB 796 BS, medium dose 1, BIRB 796 BS, medium dose 2
- Volunteers
- 182 people
- Sponsor
- Boehringer Ingelheim
Plaque Psoriasis
Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis
The main objectives of the project are: To classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in Psoriasis Area and severity Index (PASI), Psoriasis Disability…
- Trial name
- NCT00184366
- Testing
- efalizumab
- Where
- Norway
- Volunteers
- 96 people
- Sponsor
- Norwegian University of Science and Technology
Plaque Psoriasis
Bimekizumab in Plaque Psoriasis
The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies.
- Trial name
- NCT06336343
- Testing
- Bimekizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Psoriasis, Psoriatic Arthritis
Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
Psoriatic Arthritis (PsA) is a comorbidity that affects a significant proportion of participants with moderate or severe psoriasis.
- Trial name
- TOGETHER (NCT01316224)
- Where
- 15 sites in Colombia
- Volunteers
- 52 people
- Sponsor
- AbbVie (prior sponsor, Abbott)